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ric patients receiving cisatracurium during general anesthesia.
Methods: After approval of the protocol by Ethics Committee 24 pediatric patients of both sexes
aged 2–6 years, with a maximum weight 20 kg, were included in the study. Monitoring equipments
(Datex-Ohmeda A/S 5) were attached to the patient. The electromyogram was attached to one
hand, while, KMG was attached to the other hand for simultaneous monitoring. Induction of anes-
thesia with fentanyl 2 lg/kg and propofol 2 mg/kg followed by endotracheal intubation. Anesthesia
was maintained by end-tidal isoﬂurane 1.2%. Ventilation was kept by 50% oxygen in air and was
adjusted to maintain end-tidal CO2 in the range of 35–40 mm Hg. After a stable baseline period of
at least 3 min, the 24 patients were received 0.1 mg/kg cisatracurium twice the 95% effective dose
(2 · ED95). The following parameters were collected and compared; (1) lag time (time from start
of muscle relaxant administration until the ﬁrst measurable neuromuscular block (NMB), (2) onset
time (time from start of muscle relaxant administration until maximal NMB), (3) assessing the
recovery period by; train of four (TOF) 0.25, 0.50, 0.75 and 0.90 (time to reach a TOF ratio of
25%, 50%, 75% and 90%, respectively). No top-up doses of muscle relaxants were given.partment of Anesthesiology,
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248 E.A. Gaffar et al.Results: There was no statistical difference between both studied groups as regard the demographic
data of the patients, the lag time, the onset time, TOF 0.25, 0.5, 0.75 and 0.9 ratios using either
EMG or KMG. In addition, there is excellent degree of agreement between EMG and KMG in
measuring TOF ratio during both induction and recovery of muscle relaxants.
Conclusions: KMG showed an excellent degree of agreement with EMG for determination of onset
and recovery of NMB in children.
ª 2013 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
There are a limited number of studies compared KMG and
EMG in clinical practice but none of these studies compared
these two devices in children, or evaluated the effect of the type
of the muscle relaxant on data obtained by KMG versus
EMG.
This study was performed to determine whether data ob-
tained from KMG can be interchanged with data obtained
from EMG in children during general anesthesia. Adequate
control of the duration and quality of neuromuscular blockade
during surgery is essential for safe and successful surgery.
Inadequate paralysis can endanger patients, particularly dur-
ing thoracic and abdominal surgery [1–6]. Therefore, there is
a growing understanding that more attention should be paid
to objective monitoring of the degree of neuromuscular block
during and after anesthesia and to the problems of residual
curarization [7–12].
Electrical nerve stimulation is by far the most commonly
used method in clinical practice. Available methods for objec-
tive neuromuscular monitoring is mechanomyography
(MMG), EMG, KMG, phonomyography, and acceleromyog-
raphy [13–15].
MMG has long been regarded as the gold standard of neu-
romuscular monitoring in that it measures the actual force cre-
ated by muscle contraction. However, it has limitations. It was
found that data obtained from EMG did not differ signiﬁ-
cantly from that obtained from MMG [16]. So EMG has re-
placed MMG as a standard neuromuscular monitoring in
clinical practice [16].
KMG has been available for some years in the form of the
NMT-Mechanosensor integrated in the Datex anesthetic ma-
chine. It consists of a molded plastic device which can be ap-
plied into the groove of the thumb and foreﬁnger by use of
adhesive tape. In addition, as known for other methods such
as acceleromyography [17], attachment of the arm to an arm
board may increase the precision of measurement. Some stud-
ies have shown that its agreement with MMG for scientiﬁc
purposes might be limited with unacceptably wide limits of
agreement [18] in clinical circumstances. It can be used reason-
ably well to detect time to tracheal intubation and recovery of
NMB [18,19].2. Patients and methods
After Ethics Committee approval parents written informed
consent was taken this study was carried out on 24 pediatric
patients of both sexes undergoing elective surgery under
general anesthesia in Suez Canal University Hospital in theroutine surgical lists. This study was a randomized, compara-
tive clinical trial.3. Patients
3.1. Inclusion criteria
ASA I and ASA II patients aged 2–6 years of both sexes with
normal body mass index (BMI) (18–25 kg/m2) who undergoing
body surface operations, that do not require intense muscle
relaxation.3.2. Exclusion criteria
Patients with any disorders of the cardiovascular, hepatic, re-
nal, small joint arthritis or neuromuscular systems known
from history or clinical examination and investigations, pa-
tients who had taken, anticonvulsants or oral muscle relaxants,
medication known to interact with neuromuscular blocking
drugs, e.g. antibiotics (aminoglycosides, tetracyclines), anti-
arrhythmics (calcium channel blockers, quinidine) and magne-
sium sulfate .patients in whom difﬁcult intubation was
expected, and major operations, upper limb or thoracic opera-
tions were excluded from the study.4. Methods
Pre-operative assessment was carried out in the pre-operative
outpatient anesthesia clinic in Suez Canal University Hospital,
The patient’s age, sex, BMI & ASA status and type of surgery
were recorded.4.1. Anesthesia protocol
All patients were premedicated using 0.5 mg/kg midazolam per
os 30–60 min preoperatively in the pre-operative holding area.
Thereafter, cannulation of the patient by 22 or 20 gauge can-
nula was performed. Monitoring equipments (Datex-Ohmeda
A/S 5) were attached to the patient including 3 leads ECG,
automatic non-invasive blood pressure, pulse oximetry; anes-
thetic gas monitoring and temperature probe after induction
of anesthesia.
Both arms were comfortably positioned on arm boards.
The area overlying the ulnar nerve at the wrist, where the elec-
trodes to be placed, is cleaned by alcohol swap to ensure ade-
quate contact. The stimulating electrodes (Ag/AgCl ECG
electrodes for children) were stuck to the skin, which had been
Table 1 Comparison between the two studied groups regard-
ing the operative data.
Patients
No. %
ASA state
ASA I 15 62.50
ASA II 9 37.50
Type of operations
General surgery 6 25.00
Plastic surgery 2 8.33
ENT 11 45.83
Orthopedic 5 20.83
Kinemyography (KMG) versus Electromyography (EMG) 249cleaned. The electromyogram was attached to one hand, while
the kinetomyogram was attached to the other hand for simul-
taneous monitoring.
The stimulating electrodes were placed over the ulnar nerve,
which is found directly radially from the tendon of the ﬂexor
carpi ulnaris muscle as it ends in the pisiform bone of the hand.
The NMT mechano-sensor consists of two quick-ﬁt mallea-
ble plastic semicircular rings for the thumb and index ﬁnger
with an interconnecting bending strip. The piezoelectric sensor
pad, embedded in the bending strip, lies over the metacarpo-
phalangeal joint of the thumb at the angle between the index
ﬁnger and thumb. It is aligned with the ideal plane of the oppo-
sition movement of the thumb to the index ﬁnger. A narrow
adhesive tape was used to ﬁx the middle portion of the strip
in place. The ring over the thumb was also tapped. This should
not interfere with the free thumb movement.
The electromyogram electrodes were placed for stimulation
of the ulnar nerve and for recording of the compound action
potential from adductor pollicis previs muscle, using a second
Datex-Ohmeda A/S 5 monitor.
Preoxygenation with 100% oxygen for 3 min. Induction of
anesthesia with fentanyl 2 lg/kg and propofol 2 mg/kg fol-
lowed by endo-tracheal intubation.
Anesthesia was maintained by isoﬂurane 1.2%. Ventilation
by 50% oxygen in air, ventilation was adjusted to maintain
end-tidal CO2 in the range of 35–40 mm Hg. Patients were
warmed to keep the temperature of both hands constant at
P32 C and the core temperature P35 C by means of
warmed IV ﬂuids and warming blankets.
Readings of the heart rate (HR), arterial blood pressure
(ABP), oxygen saturation (SpO2), temperature (body core tem-
perature through nasopharyngeal probe and skin temperature)
and neuromuscular transmission sensors were continuously
displayed in the monitors.
Neuromuscular monitoring was carried out by supramaxi-
mal TOF stimuli up to 80 mA from Datex-Ohmeda NMT sen-
sor (2 Hz/0.5 s; pulse width 0.2 ms) every 10 s to stimulate the
ulnar nerve via surface electrodes.
After a stable baseline period for at least 3 min, the 24 pa-
tients were randomly allocated into one of two groups, KMG
group and EMG group using closed envelope method and re-
ceived cisatracurium 0.1 mg/kg twice the 95% effective dose
(2·ED95). The drug was prepared in a ﬁxed volume of 5 ml.
The following parameters were collected and compared:
Lag time: time from start of muscle relaxant administration
until the ﬁrst measurable block TOF ratio 90%.
Onset time: time from start of muscle relaxant administra-
tion until maximal neuromuscular block.
Assessing the recovery period by:
TOF 0.25 = time to reach a TOF ratio of 25%.
TOF 0.50 = time to reach a TOF ratio of 50%.
TOF 0.75 = time to reach a TOF ratio of 75%.
TOF 0.90 = time to reach a TOF ratio of 90%.
Spontaneous recovery index (dur TOF 0.25–TOF 0.9).
No top-up doses of muscle relaxants were given.
Patients were allowed to recover spontaneously from the
neuromuscular block until a stable recovery signal occurred,deﬁned as TOF ratio of P0.9 with response variation 65%
for 2 min.
At the end of surgery inhalational anesthesia was omitted,
patient ventilated with 50% oxygen in air and the patient
was extubated when TOF ratio P0.9. Any unwanted events
were recorded.
At the post anesthesia care unit, the patient was monitored
for heart rate, blood pressure, oxygen saturation, conscious le-
vel and activity.
5. Results
5.1. Demographic data
The mean age of the patients was 3.71 ± 1.15 years. Regard-
ing the weight of the patients, the mean weight of the patients
was 15.84 ± 2.86 kg. Regarding sex distribution, the fre-
quency of male patients was 14 (58.33%) and the frequency
of female patients was 10 (41.67%). As regarding ASA state
of the patients, ASA I patients represented about 62.5%, while
ASA II patients represented about 37.5%.
Pharmacodynamic time variables using EMG and KMG in
both studied groups (in seconds):
There was no statistical difference between both groups
using EMG or KMG (Table 2). This was conﬁrmed by a
strong degree of agreement between KMG and EMG in both
groups using correlation coefﬁcient test.
5.1.1. Onset phase
After cisatracurium administration, the TOF ratio of both
monitors started to decrease simultaneously. There was no sig-
niﬁcant difference in the lag and onset times measured by the
two monitors. Full block was reached in all patients indepen-
dent of the monitoring technique.
5.1.2. Recovery phase
Both monitors detected the start of recovery from NMB as
well as TOF 0.25, 0.50, 0.75 and 0.90 with excellent limits of
agreement (Table 2).
During recovery from NMB, the plotting of difference and
mean of the two monitors in TOF 0.90 showed in Fig. 1. The
correlation coefﬁcient for the strength of agreement between
both monitors was 0.992 (Table 1).
The plotting of difference and mean of the two monitors in
TOF 0.75 showed in Fig. 2. The correlation coefﬁcient for the
Table 2 Pharmacodynamic time variables (in seconds) using EMG and KMG in both studied groups.
EMG KMG Mean diﬀerence Mean (EMG+KMG)/2 t p Value a c
Mean SD Mean SD
Lag time 48.8 15.4 52.5 17.0 3.70 50.65 0.8 0.43 0.958
Onset time 186.3 54.1 191.3 55.5 5.01 188.8 0.3 0.77 0.995
TOF 0.25 25.4 3.4 25.8 3.5 0.40 25.63 0.4 0.69 0.986
TOF 0.50 45.5 4.6 45.8 4.9 0.24 45.63 0.36 0.72 0.990
TOF 0.75 55.14 5.47 55.63 5.27 0.48 55.38 0.4 0.68 0.978
TOF 0.90 66.62 6.60 67.17 6.82 0.55 66.90 0.3 0.67 0.992
Dur TOF 0.25–TOF 0.9 30.60 2.50 30.50 1.80 0.10 30.55 0.76 0.47 –
EMG= Electromyography, KMG=Kinemyography.
Insigniﬁcant p-value > 0.05.
a c=Correlation coefﬁcient description for strength of agreement: <0.6 = unsatisfactory; 0.6–0.9 = satisfactory; 0.91–1 = excellent.
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Figure 1 Bland and Altman scatter-plot of the difference
between the TOF 0.90 of the EMG and KMG against the mean
of the two measurements during recovery from NMB. The middle
dotted line represents the bias.
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Figure 2 Bland and Altman scatter-plot of the difference
between the TOF 0.75 of the EMG and KMG against the mean
of the two measurements during recovery from NMB. The middle
dotted line represents the bias.
35 40 45 50 55 60 65
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
1.5
Average of 50emg and 50kmg
50
em
g 
- 5
0k
m
g
Mean
-0.24
-1.96 SD
-1.70
+1.96 SD
1.22
Figure 3 Bland and Altman scatter-plot of the difference
between the TOF 0.50 of the EMG and KMG against the mean
of the two measurements during recovery from NMB. The middle
dotted line represents the bias.
250 E.A. Gaffar et al.strength of agreement between both monitors was 0.978
(Table 2).
The plotting of difference and mean of the two monitors in
TOF 0.50 showed in Fig. 3. The correlation coefﬁcient for the
strength of agreement between both monitors was 0.990
(Table 2).
The plotting of difference and mean of the two monitors in
TOF 0.25 showed in Fig. 4. The correlation coefﬁcient for the
strength of agreement between both monitors was 0.986
(Table 2).
6. Discussion
Monitoring the action of NMB drugs is one of the essential
components in the practice of anesthesiology. In this study,
the lag time for cisatracurium was 48.8 ± 15.4 s when moni-
tored with the EMG and 52.5 ± 17 s when monitored with
the KMG, with no statistical difference between the two mon-
itors. In addition, there was a strong agreement between the
KMG and EMG in detecting the lag time of cisatracurium
using correlation coefﬁcient test (a c= 0.95).
The lag time for cisatracurium in the presenting study was
comparable to that of the study by Carroll et al. [20] in com-
paring the NMB effects and reversibility of cisatracuriumand atracurium. They found that the median lag time of cisat-
racurium 0.1 mg/kg was 48 s with a range from to 30 to 60 s.
These ﬁndings were supported also by results of Kim et al.
[21] where the lag time of cisatracurium 0.1 mg/kg was 42
(36–48) seconds. Naguib et al. [22] also compared the clinical
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Figure 4 Bland and Altman scatter-plot of the difference
between the TOF 0.25 of the EMG and KMG against the mean
of the two measurements during recovery from NMB. The middle
dotted line represents the bias.
Kinemyography (KMG) versus Electromyography (EMG) 251pharmacology of cisatracurium and rocuronium and found
that the lag time of cisatracurium 0.1 mg/kg was 45 ± 12 s.
When comparing the EMG and KMG in detecting the lag
time of cisatracurium, there was no statistical difference be-
tween the two monitors. In addition, there was a strong degree
of agreement between KMG and EMG in detecting the lag
time of cisatracurium using the correlation coefﬁcient.
In the current study, the onset time for cisatracurium was
186.3 ± 54 s when monitored with EMG, and 191 ± 55.5 s
when monitored with KMG, with no statistical difference be-
tween the two monitors in detecting the onset time of cisatrac-
urium. Moreover, there was a strong degree of agreement
between KMG and EMG in detecting the onset time of cisat-
racurium since the correlation coefﬁcient (a c) was 0.995.
These ﬁnding were supported by results of Carroll et al. [20]
during comparing the neuromuscular blocking effects and
reversibility of cisatracurium and atracurium where the med-
ian onset time of cisatracurium 0.1 mg/kg was 162 s with a
range from to 114 to 246 s.
Also, Mellinghoff et al. [23] compared the cisatracurium
and atracurium, and found that the onset time of cisatracuri-
um 0.1 mg/kg was 186 ± 60 s. In a further study done by
Imbeault et al. [24] that assessed the pharmacokinetics and
pharmacodynamics of a 0.1 mg/kg cisatracurium in children
during N2O/O2/propofol anesthesia, the onset time was
150 ± 48 s. This shorter onset time may be due to the use of
higher dose of induction agent, propofol up to 4 mg/kg, and
N2O/O2 (70:30) and may be explained also by use of different
measuring tool, where they used the MMG in form of
relaxometer.
However in the study of Kim et al. [21] the onset time of
cisatracurium 0.1 mg/kg was 234 (180–288) seconds [mean
(95% conﬁdence intervals)]. The short onset time of cisatracu-
rium in the present study could be attributed to a more rapid
distribution of cisatracurium in children than in adult. There-
fore, the peak concentration and maximal blocking effect of
cisatracurium and the short onset time were produced sooner
in children than in adults.
In this study, the time to reach a TOF ratio of 25% for
cisatracurium was 35.8 ± 4.9 min when monitored with
EMG and 36.4 ± 5.0 min when monitored with KMG, withno statistical difference between the two monitors in detecting
the time to reach a TOF ratio of 25% of cisatracurium .
This result was supported by the ﬁndings of Lepage et al.
[25] as they studied the pharmacodynamic dose–response and
safety of cisatracurium in adult surgical patients during
N2O–O2–opioid anesthesia, where the median time taken for
25% recovery of 0.1 mg/kg cisatracurium was 33 min with
the range of 22–50 min. Also, Imbeault et al. [24] found that
the recovery of cisatracurium 0.1 mg/kg to T25% time was
37.6 ± 10.2 min.
However, Carroll et al. [20] during studying the NMB ef-
fects and TOF fade of cisatracurium compared with other
non-depolarizing relaxants, found that the median time from
0.1 mg/kg cisatracurium injection to the recovery of a TOFR
of 0.25 was 41 (20.6–50.0) min.
In addition, Hans et al. [26] during comparing the recovery
from NMB after an intubating dose of cisatracurium and rocu-
ronium in adults found that the time from 0.1 mg/kg cisatrac-
urium injection to the recovery of a TOFR of 0.25 was
49.8 ± 5.3 min. In their study, anesthesia was induced with
IV sufentanil 0.15 lg kg1, ketamine 0.15 mg kg1 and propo-
fol 2 mg kg1 and maintained with sevoﬂurane (1.5–2% end ti-
dal) and 60% nitrous oxide in oxygen. Neuromuscular
transmission was monitored at the wrist by accelerometry
using the TOF-Guard monitor.
In the present study, the time to reach a TOF ratio of 50%
for cisatracurium was 45 ± 4.6 min when monitored with
EMG, and 47.8 ± 4.8 min when monitored with KMG, with
no statistical difference between the two monitors in detecting
the time to reach a TOF ratio of 50% of cisatracurium.
Similar results were recorded by Imbeault et al. [24] since
they found that the mean time from injection of cisatracurium
to recovery of the TOF ratio to 0.4 were 42.6 ± 8.3 min.
However, Hans et al. [26] in studying the recovery from
neuromuscular block after an intubating dose of cisatracurium
and rocuronium in adult patients found that the time from
0.1 mg/kg cisatracurium injection to the recovery of a TOFR
of 0.5 was 61 ± 6.2 min. In their study, anesthesia was induced
with IV sufentanil 0.15 lg kg1, ketamine 0.15 mg kg1 and
propofol 2 mg kg1 and maintained with sevoﬂurane (1.5–
2% end tidal) and 60% nitrous oxide in oxygen. Neuromuscu-
lar transmission was monitored at the wrist by accelerometry
using the TOF-Guard monitor.
In this study, the time to reach a TOF ratio of 75% for
cisatracurium was 55.0 ± 5.4 min when monitored with
EMG, and 55.6 ± 5.3 min when monitored with KMG, with
no statistical difference between the two monitors in detecting
the time to reach a TOF ratio of 75% of cisatracurium.
This ﬁnding was in accordance with the results Lepage et al.
[25] in studying pharmacodynamic dose–response and safety
study of cisatracurium in adult surgical patients during
N2O–O2–opioid anesthesia, where the median time taken for
TOF 0.7 recovery of 0.1 mg/kg cisatracurium was 53 min with
the range of 32–72 min. Also, Meretoja et al. [27] in assessing
cisatracurium during halothane and balanced anesthesia in
children found that the median time of 0.1 mg/kg cisatracuri-
um to the recovery of TOF ratio to 0.7 was 56.5 (38.3–
61.2) min.
In addition, Jellish et al. [28] agree with the present result in
studying the recovery from neuromuscular blockade after both
bolus and prolonged infusions of cisatracurium or rocuroni-
um, where they established the median time to recovery of
252 E.A. Gaffar et al.TOF ratio to 0.75 was 50.1 (31.4–59.5) min after bolus injec-
tion of 0.1 mg/kg cisatracurium.
However, Imbeault et al. [24] found that the recovery to
TOF ratio to 0.7 was 49.1 ± 9.2 min for cisatracurium
0.1 mg/kg dosage. Meretoja et al. [27] in assessing cisatrac-
urium during halothane and balanced anesthesia in children
found that the median time of 0.1 mg/kg cisatracurium to
the recovery of TOF ratio to 0.7 was 56.5 (38.3–
61.2) min. Further, Maybauer et al. [29] in studying the
incidence and duration of residual paralysis at the end of
surgery after multiple administrations of cisatracurium and
rocuronium, the recovery time of 0.1 mg/kg cisatracurium
till TOFR of 0.7 was 44 ± 8 min. Also, Amin et al. [30]
in a comparative study of neuromuscular blocking and
hemodynamic effects of rocuronium and cisatracurium un-
der sevoﬂurane or total intravenous anesthesia, found that
the time till recovery of 0.1 mg/kg cisatracurium till TOF
0.75, was 44 ± 6.4 min.
Moreover, Maybauer et al. [29] in evaluating the incidence
and duration of residual paralysis at the end of surgery after
multiple administrations of cisatracurium and rocuronium,
the recovery time of T4/T1 to 0.7 was 58 ± 28 min following
0.6 mg/kg rocuronium.
In this study the time to reach a TOF ratio of 90% for cisat-
racurium was 66.4 ± 6.6 min when monitored with EMG, and
67.0 ± 6.8 min when monitored with KMG, with no statistical
difference between the two monitors in detecting the time to
reach a TOF ratio of 90% with cisatracurium.
This result was supported by Barrio et al. [31] in studying
the neuromuscular recovery of rocuronium and cisatracurium
after early, late or no reversal with neostigmine, the recovery
of TOF ratio to 0.9 was 62.2 ± 8.8 min. Additionally, Carroll
[20] in assessing the neuromuscular blocking effects and train-
of-four fade with cisatracurium, supported our results as the
time to TOF 0.8 after cisatracurium 0.1 mg/kg was 65 (39.6–
77.7).
Imbeaultetal.[24]in2005foundthattherecoverytoTOFratio
to 0.9 was 56.6 ± 11 min of cisatracurium 0.1 mg/kg. In their
study,themeanageofsubjectswas3.7 yearsandanesthesiawasin-
ducedwith a bolus dose of fentanyl (1–2 lg/kg) and propofol (2–
4 mg/kg) as well as maintained with propofol (150 lg/kg/min)
andN2O/O2 (70:30).
Moreover, Maybauer et al. [29] found that the recovery time
of 0.1 mg/kg cisatracurium till TOFR of 0.9 was 51 ± 8 min.
Anesthesia was induced with propofol (1.5–2.5 mg/kg) and fen-
tanyl (4–8 lg/kg), and was maintained with propofol (5–10 mg/
kg/h) and remifentanil (0.05–2 lg/kg/min). They use repeated
doses of cisatracurium rather than a single bolus dose.
Furthermore, Carroll et al. [20] in 1998 compared the NMB
effects and reversibility of cisatracurium and atracurium where
the median recovery time to TOF 0.8 after cisatracurium
0.1 mg/kg was 74 min with a range from 62 to 86 min. How-
ever there was some limitations in our study, ﬁrst was that
we compared KMG versus EMG using the same NMTmodule
for Datex ohmeda monitor that may explain the excellent de-
gree of agreement between the two sensors. Second limitation
was that the use of pediatric KMG sensor is limited to patient
not more than 20 kg, according to the manufacture guide so in
using KMG in clinical practice we cannot use pediatric sensor
in patients heavier than 20 kg till adult age group where adult
sensor is used.References
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